Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Liabilities and Shareholders Equity (2020 - 2025)

Historic Liabilities and Shareholders Equity for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to $205.0 million.

  • Foghorn Therapeutics' Liabilities and Shareholders Equity fell 3353.42% to $205.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $973.9 million, marking a year-over-year decrease of 1731.98%. This contributed to the annual value of $284.0 million for FY2024, which is 67.64% down from last year.
  • Latest data reveals that Foghorn Therapeutics reported Liabilities and Shareholders Equity of $205.0 million as of Q3 2025, which was down 3353.42% from $226.2 million recorded in Q2 2025.
  • Foghorn Therapeutics' Liabilities and Shareholders Equity's 5-year high stood at $519.8 million during Q4 2021, with a 5-year trough of $186.1 million in Q3 2021.
  • Over the past 5 years, Foghorn Therapeutics' median Liabilities and Shareholders Equity value was $308.4 million (recorded in 2024), while the average stood at $321.4 million.
  • Per our database at Business Quant, Foghorn Therapeutics' Liabilities and Shareholders Equity surged by 13321.03% in 2022 and then crashed by 3353.42% in 2025.
  • Over the past 5 years, Foghorn Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $519.8 million in 2021, then decreased by 22.1% to $404.9 million in 2022, then fell by 29.38% to $285.9 million in 2023, then fell by 0.68% to $284.0 million in 2024, then decreased by 27.83% to $205.0 million in 2025.
  • Its last three reported values are $205.0 million in Q3 2025, $226.2 million for Q2 2025, and $258.7 million during Q1 2025.